BEGIN:VCALENDAR
PRODID:-//github.com/rianjs/ical.net//NONSGML ical.net 4.0//EN
VERSION:2.0
BEGIN:VEVENT
DESCRIPTION:16th Biosimilars Congregation 2021\n\n“Uniting industry leader
 s to analyse advanced commercial developments &amp\; identify successful 
 management strategies of Biosimilars”\n\n09th December 2021\, Virtual Con
 ference (Time Zone – IST)\n\nVirtue Insight is delighted to invite you to
  attend the 16th Biosimilars Congregation 2021 conference\, to be held on
  09th December 2021(Virtual Conference). 16th Biosimilars Congregation 20
 21 brings together scientists\, researchers and CROs from around the worl
 d. At 16th Biosimilars Congregation 2021 meet your target audiences from 
 around the world focused on learning about biologics and biosimilars. Thi
 s conference would be your single best opportunity to reach the largest a
 ssemblage of participants from the biologics and biosimilars community\n\
 nDELEGATE REGISTRATION:\n\nE-mail - kavitha@virtueinsight.co.in or Call M
 : +91 9361957193 or T: +91 44 24762472\n\nPlease note that this is a PAID
  event and NOT A FREE event (no complimentary passes available). Any invi
 te\, email or tickets issued mentioning it as a free pass or free ticket 
 to this event through any third party site will strictly not be accepted 
 by the organizer.&nbsp\; \n\n\nEarly Bird Price (Valid Till 12th Nov 2021
 ) – (INR 6\,000 + GST (18%) per delegate) \nStandard Price (Valid From 13
 th Nov 2021) – (INR 8\,000 + GST (18%) per delegate) \n\nConference Spons
 or\, Exhibition Stall &amp\; Paid Speaker Slot - Please email your intere
 st and queries to kavitha@virtueinsight.co.in\n\nKEY SPEAKERS:\n\n\nARANI
  CHATTERJEE\,&nbsp\;Senior Vice President\, Clinical Research\,Aurobindo\
 nPHILIP SCHNEIDER\, Chair\, International Advisory Board\,&nbsp\;Alliance
  for Safe Biologic Medicines(USA)\nMICHEL MIKHAIL\,&nbsp\;International E
 xpert in Regulatory Affairs\,&nbsp\;Global Expert in Biosimilars (Germany
 )\nRAHUL GUPTA\,&nbsp\;Vice President\, Regulatory Affairs\,USV\nMARTA BA
 LDRIGHI\,&nbsp\;Policy and Science Officer\,Medicines for Europe (Belgium
 )\nSHALIGRAM RANE\,&nbsp\;Vice President of Quality\,&nbsp\;Lupin\nNAREND
 RA MAHARAJ\,&nbsp\;Vice President and Head\, Clinical Development and Bio
 logics\, Reddy's Laboratories\nDIVYA BIJLWAN\,&nbsp\;Senior Vice Presiden
 t\, Business Development\,Aurobindo\nPRAVEEN KUMAR L\,Director - Regulato
 ry Affairs\,&nbsp\;Cipla\nPIRTHI PAL SINGH\,&nbsp\;Associate Vice Preside
 nt\, Head R&amp\;D - Differentiated Formulations\, Reddy's Laboratories\n
 PAWAN SINGH\,&nbsp\;Senior Medical Director\,Biocon\nKUMAR GAURAV\,Direct
 or Medical Affairs\,&nbsp\; Reddy's Laboratories\nMILIND ANTANI\,&nbsp\;L
 eader\, Pharma and Healthcare\,&nbsp\;Nishith Desai Associates\nARUN BHAT
 T\,&nbsp\;Consultant – Clinical Research &amp\; Development\nNITISH CHAKR
 AVARTY\,&nbsp\;Vice President - Secondary Manufacturing\,&nbsp\;Biologica
 l E. Limited\nKANTHIKIRAN&nbsp\;VARANASI\,&nbsp\;Vice President and Head 
 - Clinical Research &amp\; Operations\,&nbsp\;Galenicum\nGAURAV SAHAL\,&n
 bsp\;Head of Global Patent Prosecution\,&nbsp\;Sun Pharma\nADITYA SHARMA\
 ,&nbsp\;Head - BioProcessing Business\,&nbsp\;Merck Life Science\nNIBEDIT
 A RATH\,&nbsp\;Scientific Director\,&nbsp\;Open Source Pharma Foundation&
 nbsp\;\nUDIT SAKHUJA\,&nbsp\;Head Of Marketing\, Reddy's Laboratories\nSO
 NAL SHAH\,&nbsp\;Head Marketing – Biosimilars\,Cadila\nSWEETY MATHEW\,&nb
 sp\;Global Regulatory Affairs\,&nbsp\;Biocon\nRAHUL CHAUHAN\,&nbsp\;Head-
  Regulatory Affairs\,&nbsp\;Takeda\nALOK SHARMA\,&nbsp\;Head &amp\; GM\, 
 Quality Control\,&nbsp\;Lupin\nTUSHAR NAIK\,&nbsp\;Consultant &amp\; Advi
 sor\, GLG(USA) (Former Senior GM\, Zydus Group)\nRAVI SHANKARA\,&nbsp\;Se
 nior General Manager (R &amp\; D) &amp\; Functional Head -Analytical Deve
 lopment - Biologics and Peptides\,Sun Pharma\nMAHENDRA SHIRADKAR\,&nbsp\;
 Lead: FDS Project and Portfolio Management\,Viatris\nPRAVIN A. NAIR\,&nbs
 p\;Head Drug Product Development (R&amp\;D)\,&nbsp\;Intas Pharmaceuticals
  (Biopharma Division)\nKAVYA KADAM\,&nbsp\;Consultant\, Global Clinical T
 rials\nHARSHAD KOTHAWADE\,&nbsp\;Head-Regulatory Management &amp\; Trade 
 Compliance\,Merck\n\nKEY THEMES DISCUSSED:\n\n\nRecent trends and new nor
 mal in Biosimilars - How to excel with this?\nDevelopment challenges on t
 he biosimilars products for companies? What are the remedies?\nPharmacovi
 gilance and risk management of biosimilars.\nSuccessful business models a
 nd dealing with every ambiguity mAbs - Could be a game changer in India\n
 Impact of the pandemic - affecting the biosimilar markets\nWays for smart
  handling of market access\, sustainable pricing and reimbursement of bio
 similars in the market.\nChallenges and changes interchangeability\nHow d
 oes strategic planning really help to grow market opportunities?\nMarket 
 barriers for biosimilar approval in India market.\nFuture opportunities f
 or product development\nRisk of adverse effects related to new drug devel
 opment. How to overcome that?\nNewer versions of generic drugs truly incr
 ease the value of the market?\nHow to speed up the process of development
  and reduce costs of production?\nRegulators view on interchangeability a
 nd switching biosimilars.\nHow to minimise the rejection of biosimilar ap
 plications while evaluating regulatory bodies?\nNext 5 years in the field
  of biosimilars regulations\n\nWHO SHOULD ATTEND AND WHO YOU’LL MEET:\n\n
 CSOs\, CMOs\, Vice Presidents\, Presidents\, Heads\, Directors\, Team Lea
 ders\, and Senior Scientists from the following roles:\n\nBiopharmaceutic
 als/Biotherapeutics\, Follow on Biologics/Follow on Proteins\, Biologics/
 Biotechnology/ Bio generics\, Legal Affairs\, Intellectual Property\, Hea
 lth Economics\, Pricing and Reimbursement\, Clinical Immunology\, Princip
 al Scientist\, Chief Scientific Officer\, Process Control and Analytical 
 Technologies\, Analytical Characterisation\, Regulatory Compliance\, Phar
 macovigilance\, Drug Safety &amp\; Risk Management\, Quality Affairs/ Qua
 lity Control\, New Product Development\, Process Science\, Portfolio Mana
 gement\, Research &amp\; Development\, Business Development\, Business Op
 erations\, Scientific Affairs\, Commercial Affair\n\nGet more from the ev
 ent\, with a broader scope bringing the whole communications value chain 
 together. Enjoy and make the best out of our dedicated networking time\, 
 meet the leading international vendors showcasing the products of tomorro
 w in the co-located exhibition. Expand your knowledge of the latest busin
 ess models and strategies in the high-level conference.\n
DTEND:20211209T173000
DTSTAMP:20260415T140752Z
DTSTART:20211209T093000
LOCATION:\,
SEQUENCE:0
SUMMARY:16th Biosimilars Congregation 2021\n“Uniting industry leaders to a
 nalyse advanced commercial developments &amp\; identify successful manage
 ment stra...
UID:05f4bf7b-55f5-4deb-ae59-4127621a6187
END:VEVENT
END:VCALENDAR